Sustainable Impact Report: DLRC Commits to Net Zero by 2050

DLRC, an award-winning global regulatory affairs consultancy supporting the development and licensing of pharmaceutical, biotech, advanced therapy and medtech products worldwide, has published its 2024 Sustainable Impact Report. This report highlights the significant strides the company has made in environmental sustainability, community engagement, and corporate governance. The report shows that DLRC has raised £32,200 for charity while establishing a commitment to achieve Net Zero carbon emissions by 2050.

In her opening remarks, CEO Dianne Lee reflects on a year of transformation: “We continue to implement new initiatives and collaborate with external consultants to address our most significant sustainability impacts.”

As a company that maintains regulatory compliance while choosing to be transparent, DLRC publishes sustainability metrics to demonstrate how responsible business practices drive positive impact and exceptional client results.

Key Highlights from the Sustainable Impact Report 2024

DLRC re-benchmarked its carbon footprint using enhanced data collection methods, achieving 1.63 tCO2e per full-time employee. The company developed a detailed plan to achieve Net Zero Carbon Emissions by 2050, working with external consultants to address scope 3 emissions. DLRC also secured landlord commitments for significant building improvements. These include gas boiler removal and energy efficiency upgrades by 2030, directly supporting emission reduction targets.

DLRC team members raised £32,200 across eight charitable organisations. Key contributions included £626 for MIND, £480 for Age UK, and £466.25 for Macmillan Cancer Support. DLRC expanded its outreach through partnerships with Mission 44 and Herts County Council, delivering employability workshops and STEM career events. The company expanded STEM education support through work experience for 7 students.

Governance milestones achieved:

ISO 9001:2015 certification
B-Corp evaluation stage reached
The Third King’s Award for Excellence in International Trade was received
Cyber Essentials Plus certification

With nearly 75% of its workforce identifying as female and 25% from ethnic minority backgrounds, DLRC continues to champion diversity, equity, and inclusion. DLRC introduced new policies on wellbeing, menstrual health, menopause, and domestic abuse, and retained its Investors in People Silver Award. The organisation promoted 15 team members during 2024 while supporting 9 UK apprentices, representing approximately 10% of the workforce.

Despite ESG investments, DLRC maintained exceptional client satisfaction with 10/10 ratings for recommendation likelihood and communication effectiveness. This proves sustainability initiatives enhance rather than compromise business performance.

A Shared Vision for the Future

Key commitments of DLRCs 2025 Sustainability Roadmap include:

Implementing electric vehicle salary sacrifice schemes
Establishing a cross-departmental sustainability committee
Expanding environmental training for all employees
Continuing landlord collaboration on building improvements

To close the report, CEO Dianne Lee states, “We will continue to review and adjust our priorities, ensuring that we stay on track and make meaningful contributions to global sustainability efforts. Together we can build a more sustainable future for all.” View our full 2024 Sustainable Impact Report here.

Hear from DLRC’s Sustainability Manager, Charlotte Biddlecombe

“I’m proud to be part of a team at DLRC that’s always striving to do better – for the environment, for our community, and for global health. We’re constantly working to improve the accuracy of our carbon reporting, find meaningful ways to reduce our footprint, and support the people and places around us.”

About DLRC

Advancing Global Patient Healthcare Through Regulatory Excellence

DLRC provides global life science companies with a wide range of regulatory affairs consulting services. DLRC is an award-winning consultancy of more than 80 highly qualified, experienced regulatory professionals and support functions operating from offices in the UK, Germany, and the US. Demonstrating a deep commitment to excellence, the team helps clients navigate the complex regulatory landscape of the life science industry by developing and executing innovative regulatory strategies, and by providing comprehensive support from early development to post-licensing activities for medicinal products and medical devices. DLRC’s regulatory team includes consultant experts in nonclinical, CMC, clinical and MedTech from pharmaceutical, medical device and regulatory agency backgrounds. DLRC has proudly served companies of all sizes and backgrounds in various regulatory jurisdictions.